EyePoint PharmaceuticalsEYPT
EYPT
About: EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Employees: 144
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
39% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 18
22% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 46
18% more call options, than puts
Call options by funds: $1.63M | Put options by funds: $1.38M
4% more funds holding
Funds holding: 145 [Q4 2024] → 151 (+6) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
1.29% less ownership
Funds ownership: 109.06% [Q4 2024] → 107.77% (-1.29%) [Q1 2025]
27% less capital invested
Capital invested by funds: $553M [Q4 2024] → $401M (-$152M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
144%
upside
Avg. target
$25
177%
upside
High target
$27
199%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen | 144%upside $22 | Buy Reiterated | 29 May 2025 |
Mizuho Graig Suvannavejh | 188%upside $26 | Outperform Maintained | 16 May 2025 |
Chardan Capital Daniil Gataulin | 199%upside $27 | Buy Maintained | 8 May 2025 |
Financial journalist opinion
Based on 5 articles about EYPT published over the past 30 days
Neutral
Seeking Alpha
3 days ago
EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026
EyePoint Pharmaceuticals, Inc.'s Duravyu shows promising Phase 2 results in DME, supporting a slightly risky 'Buy' call ahead of pivotal Phase 3 readouts in 2026. Duravyu's potential for less frequent dosing could offer a key advantage over current market leaders Eylea and Vabysmo. Rapid enrollment in Phase 3 trials and robust safety/efficacy data boost confidence, but competition and market fragmentation remain significant risks.
Neutral
MarketBeat
1 week ago
Breakout Momentum Plays You May Not Know About
High volatility has plagued markets throughout much of 2025. While many consider this a bad thing, particularly when trends point downward, it can also create opportunities for momentum investors to capture gains when target stocks are up.
Neutral
GlobeNewsWire
2 weeks ago
EyePoint Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate in fireside chats at the following upcoming investor conferences:
Neutral
GlobeNewsWire
2 weeks ago
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration
– Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest –
Neutral
GlobeNewsWire
4 weeks ago
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
EyePoint Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming investor conferences: RBC Capital Markets Global Healthcare Conference Forum: Fireside ChatDate: Tuesday, May 20, 2025Time: 10:00 a.m.
Neutral
Seeking Alpha
1 month ago
EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants George Elston - Executive Vice President & Chief Financial Officer Jay Duker - President & Chief Executive Officer Ramiro Ribeiro - Chief Medical Officer Conference Call Participants Jennifer Kim - Cantor Tessa Romero - JPMorgan Tyler Van Buren - TD Cowen Yatin Suneja - Guggenheim Kambiz Yazdi - Jefferies Nick Quartapella - Baird Deb Chatterjee - Jones Yale Jen - Laidlaw & Company Yigal Nochomovitz - Citigroup Operator Good morning. My name is Towanda and I will be your conference operator today.
Positive
Zacks Investment Research
1 month ago
EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for EyePoint Pharmaceuticals (EYPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Neutral
Zacks Investment Research
1 month ago
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.65 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.55 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments
– Enrollment continues to exceed expectations in DURAVYU ™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing confidence in enrollment completion in 2H 2025 and expected first-to-market advantage – – $318 million of cash, cash equivalents and marketable securities as of March 31, 2025, provides cash runway into 2027, beyond topline data for both Phase 3 wet AMD trials expected in 2026 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the first quarter ended March 31, 2025, and highlighted recent corporate developments.
Charts implemented using Lightweight Charts™